TOP TIERMARKET NEWSWIRE
News & sentiment

AMYLYX PHARMACEUTICA (AMLX) — News & AI sentiment

AMYLYX PHARMACEUTICA (AMLX) news roundup. 3 stories aggregated over the last 30 days. Average 30-day sentiment is 58.7/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 6 sales totalling $3.8M — net selling of $3.8M. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →
24h stories
0
7d stories
0
30d stories
3
avg sentiment 58.7/100
Insider net (90d)
$3.8M
0 buys · 6 sells
Congress (90d)
0
0 buys · 0 sells

AMLX news in the last 24 hours, 7 days, 30 days and 90 days

How much AMLX coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time windowAMLX storiesAvg AI sentimentRead
Last 24 hours0—no coverage
Last 7 days0—no coverage
Last 30 days358.7/100AMLX headlines →
Last 90 days8458.3/100AMLX headlines →

Latest stories on AMLX

Oct 15
Oct 6
Stifel reiterates Amylyx stock rating on avexitide confidence
Investing.com Analyst Ratings56 · neutralanalyst
Oct 1
Sep 23
Sep 23
Sep 16
Sep 9
Sep 8
Sep 8
Sep 8
Sep 1
Sep 1
Aug 30
Aug 30
Guggenheim raises Amylyx stock price target on financing, trial data
Investing.com Analyst Ratings61 · neutralanalyst
Aug 27
Aug 27
Aug 22
Aug 21
Aug 21
Aug 21
Aug 20
Aug 20
Aug 20
Aug 20
Aug 20
Open AMLX in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →